3
2
1

Light-Speed Thawing of Oocytes: 2D Material + Laser Raises Recovery Survival Rate to 81%

Release time:

2026-09-24

In assisted reproduction, vitrification cryopreservation of oocytes (eggs) is a key technology for preserving female fertility. However, conventional thawing methods often fail to warm samples quickly enough, causing ice crystals to re-form and damaging cellular structures. Recently, ACS Omega published an innovative study: a research team combined the 2D material Ti₃C₂Tₓ MXene with an 808 nm near-infrared laser to achieve rapid photothermal rewarming of oocytes, significantly improving survival rate and cellular function and offering a new approach for fertility preservation.

Freezing Is Easy, Revival Is Hard: The Overlooked “Rewarming Window”

Oocyte cryopreservation is a key technology for protecting female fertility and preserving the genetic resources of endangered species. Its difficulty lies in the fact that eggs are large, have high water content, and have sensitive membrane structures, making them extremely vulnerable to temperature changes.

The mainstream clinical approach is vitrification: using high concentrations of cryoprotectants together with ultra-rapid cooling to turn the intracellular fluid directly into an amorphous glassy state, bypassing the lethal damage caused by ice crystals. Since Kuleshova et al. reported the first live birth from a vitrified egg, this approach has been repeatedly validated.

But cooling is only the first half. The real bottleneck is devitrification during rewarming: when the sample temperature rises and crosses the glass transition temperature (Tg, approximately −120 °C to −130 °C in conventional cryoprotectant systems), the stable glassy state re-precipitates crystals, i.e., “recrystallization.” Once ice crystals grow, the cell ultrastructure is likely to suffer severe damage. Data cited in the paper show that this window varies with solution formulation; for example, Sansinena et al. measured a range of −126 °C to −121 °C.

The conclusion is straightforward: rewarming rate is the rate-limiting step determining the success or failure of cryopreservation. Although reducing carrier volume can improve heat conduction efficiency, recovery survival rates are still far from ideal. Since conventional heating is not fast enough, accelerating heat generation inside the sample has become a new idea.

 

Putting MXene into the Cryoprotectant: Letting Heat Rise Uniformly from Within

The material selected for the study is Ti₃C₂Tx MXene—a 2D transition metal carbide first reported in 2011, combining metal-like conductivity with outstanding photothermal conversion capability. After preparation by LiF-HCl etching, characterization confirmed that it has an ultrathin nanosheet morphology, with a thickness of only 0.4–0.8 nm; its surface is dominated by C-Ti and Ti-O bonds and -OH/-F terminal groups, and its total weight loss under a nitrogen atmosphere is only 7.86%.

Next came parameter optimization. The MXene-doped cryoprotectant was irradiated with an 808 nm near-infrared laser, and combinations of laser power (0–3 W/cm²) and MXene concentration (0–1 mg/mL) were examined: concentration was positively correlated with rewarming rate, but the gain weakened markedly above 0.6 mg/mL; 3 W/cm² caused protein denaturation and reduced oocyte viability. Considering both photothermal efficiency and biocompatibility, 0.6 mg/mL MXene + 2 W/cm² laser was the optimal scheme, raising the straw temperature to 40 °C within 10 s.

Physical evidence was also obtained: after adding MXene, the average maximum ice crystal grain size decreased significantly; DSC showed that melting enthalpy increased with concentration while crystallization temperature remained relatively stable, indicating that although it promoted heterogeneous nucleation, it did not increase the total amount of crystallization. To address the problems of straw buoyancy drift at the air-liquid interface and inaccurate laser focusing, the team also designed an integrated rewarming platform, using an S-shaped fixture to lock the straw within the laser working range.

 

Beyond 81% and 72.1%: Functional Evidence Behind the Survival Rate

Toxicity is a mandatory question for nanomaterials entering biological applications. Mouse oocytes were co-cultured at 37 °C and 5% CO₂ in cryoprotectant with and without 0.6 mg/mL MXene. AO/EB dual fluorescence staining showed that during the first 4 hours, both groups had high survival rates and intact morphology; after 8 hours, both groups dropped to 0%, which the paper explained as being due to acidification of M2 medium in the CO₂ incubator rather than material toxicity. Microscopy also confirmed that the solution transfer and dilution procedures could completely wash the nanomaterial off the surface of the zona pellucida.

The core result was survival rate: 81.0 ± 3.2% in the MXene group versus 72.1 ± 5.7% in the conventional vitrification group, a statistically significant difference (p < 0.01). But survival does not equal health. Three functional indicators showed: reactive oxygen species levels were lower than in the conventional group and only slightly higher than in the fresh group; intracellular calcium homeostasis was better than in the conventional group; and mitochondrial membrane potential was close to that of the fresh group.

The paper also clearly states its limitations: the long-term biosafety of MXene still needs to be evaluated to confirm that it does not affect subsequent embryo development and reproductive potential; the S-shaped platform and external laser components have limited integration and still require optimization before clinical application. The path validated by this work is clear—allowing samples to rapidly and uniformly traverse the dangerous temperature zone from within to suppress devitrification, providing a useful approach for the cryopreservation of oocytes and even embryos and organs.

 

Paper information: Fang, Z.; Li, S.; Liu, R.; Yuan, Z.; Yin, L.; Chen, Z. Ti₃C₂Tx MXene Combined with Laser Photothermal for High-Performance Oocyte Cryopreservation. ACS Omega 2026, 11, 56492−56503. DOI: 10.1021/acsomega.6c07760

Latest developments

【The YinFeng Life Continuation Project Debuts at the 2026 Annual Meeting of the Chinese Medical Association's Medical Ethics Branch—Ethics Leading Biotech Toward Benevolent Innovation】

The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.

Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross

Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.

Yinfeng Life Science Research Institute, in Collaboration with University of Science and Technology of China, Develops CryoSIM Platform, Published in Top Analytical Chemistry Journal Revolutionizing Oocyte Membrane Permeability Analysis Technology

The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).

World’s First Achievement Highlights Brand Leadership

In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.

Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference

Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.